BB Biotech AG : Post Q2 2023 update. Target price adjusted to € 57
>BB Biotech held an analysts’ presentation yesterday - BB Biotech’s management held an analysts’ meeting yesterday to discuss recent business trends following the release of Q2 2023 results. Our key takeaways are: 1/ the continued pursuit of the investment strategy; 2/ better M&A momentum than in 2022 and a priority given to partnership-type deals; and 3/ a clinical and regulatory newsflow that continues to help offset macroeconomic pressures in recent months.§hp...Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.